Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
6.30
+0.03 (0.40%)
Jan 13 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.22 - 6.40
52 week 4.03 - 9.40
Open 6.35
Vol / Avg. 11,514.00/16,353.00
Mkt cap 76.07M
P/E     -
Div/yield     -
EPS -1.15
Shares 12.03M
Beta 0.83
Inst. own 26%
Mar 6, 2017
Q4 2016 Chembio Diagnostics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 16, 2016
Chembio Diagnostics Inc at Craig-Hallum Alpha Select Conference
Nov 10, 2016
Q3 2016 Chembio Diagnostics Inc Earnings Call
Nov 10, 2016
Q3 2016 Chembio Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -57.07% -9.88%
Operating margin -57.23% -14.65%
EBITD margin - -8.99%
Return on average assets -48.49% -10.46%
Return on average equity -59.55% -12.82%
Employees 155 -
CDP Score - -

Address

3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Javan Esfandiari Chief Science and Technology Officer
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 63
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Gary Meller M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters